NDC 0524
Alternative Names: NDC-0524Latest Information Update: 18 Jun 2024
At a glance
- Originator Nitrase Therapeutics
- Class Antiparkinsonians
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease